Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-51
SponsorWolfson Medical Center
About this trial
The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more).
The main questions it aims to answer are:
* Does topical TXA shorten uterine closure time? * Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes.
Participants will:
* Be randomly assigned to receive either topical TXA or placebo during cesarean delivery. * Have standard surgery and postoperative care identical in both groups. * Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.
Eligibility criteria
Qualifiers
Women aged 18 to 51 years
Singleton pregnancy
Elective cesarean delivery scheduled at ≥37+0 weeks of gestation
First or second cesarean delivery only
Disqualifiers
Known allergy or hypersensitivity to tranexamic acid (TXA)
History of bleeding or coagulation disorders
Previous postpartum hemorrhage
Placenta previa or placenta accreta spectrum
Trial design
Treatments tested in this trial
- Tranexamic Acid (Topical)
- Normal Saline (Placebo)
Treatment groups
112 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wolfson Medical Center
Lead sponsor
Rabin Medical Center
Collaborator
Meir Medical Center
Collaborator
Kaplan Medical Center
Collaborator
Source ClinicalTrials.gov